Short answer
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results announced by Maravai LifeSciences.
MARAVAI LIFESCIENCES HOLDINGS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced by Maravai LifeSciences
- Full results and management commentary furnished in Exhibit 99.1
- Investors should review the exhibit for revenue, profitability, guidance, and operating trends
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $51.4M, up 8.5% year over year, led by TriLink growth of 11.5%
- Adjusted EBITDA $8.7M versus $(10.4)M, signaling substantial operating leverage despite $21.6M net loss
- Full-year Adjusted EBITDA guidance raised to $33M–$35M from $30M–$32M
- 2026 revenue guidance maintained at $205M–$215M, with six-month revenue up 24.4%
- TriLink’s six-month growth includes $14.3M of COVID CleanCap orders, creating potential comparability and durability risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MARAVAI LIFESCIENCES HOLDINGS, INC. 8-K filings
Get the next MRVI 8-K as it lands
Follow MRVI for push alerts, or ask the research agent what this filing means.